Arcus Biosciences Inc (RCUS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Terry J. Rosen
Employees:
370
3928 POINT EDEN WAY, HAYWARD, CA 94545
650-489-9000

Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.

Data derived from most recent annual or quarterly report
Market Cap 1.644 Billion Shares Outstanding71.06 Million Avg 30-day Volume 1.271 Million
P/E Ratio24.4514 Dividend Yield0.0 EPS
Price to Revenue4.3658 Debt to Equity0.0 EBITDA93.445 Million
Price to Book Value2.7046 Operating Margin17.4908 Enterprise Value697.781 Million
Current Ratio6.215 EPS Growth0 Quick Ratio5.939
1 Yr BETA 1.6304 52-week High/Low 39.75 / 16.74 Profit Margin18.4417
Operating Cash Flow Growth282.6766 Altman Z-Score2.4582 Free Cash Flow to Firm 365.58 Million
View SEC Filings from RCUS instead.

View recent insider trading info

Arcus Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RCUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RCUS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-25 by NUYTEN DIMITRY SA
  • 4: filed on 2023-01-25 by GOELTZ II ROBERT C.
  • 4: filed on 2023-01-25 by TANG CAROLYN C.
  • 4: filed on 2023-01-25 by JARRETT JENNIFER
  • 4: filed on 2023-01-25 by JAEN JUAN C.
  • 4: filed on 2023-01-25 by ROSEN TERRY J
  • 4: filed on 2022-09-20 by JARRETT JENNIFER
  • 4: filed on 2022-08-24 by NUYTEN DIMITRY SA
  • 4: filed on 2022-06-21 by TANG CAROLYN C.
  • 4: filed on 2022-06-21 by ROSEN TERRY J

    • Events (8k)

  • 8-K: filed on 2022-12-19:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-28:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-21:
    Item 8.01: Other Events
  • 8-K: filed on 2021-11-18:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    38.9 Thousand total shares from 10 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ROSEN TERRY J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 4,331,993 2023-01-23 4

    JAEN JUAN C. PRESIDENT

    • Officer
    • Director
    		 1,732,822 2023-01-23 5

    GOELTZ II ROBERT C. CHIEF FINANCIAL OFFICER

    • Officer
    		 201,641 2023-01-23 3

    JARRETT JENNIFER CHIEF OPERATING OFFICER

    • Officer
    • Director
    		 602,746 2023-01-23 6

    NUYTEN DIMITRY SA CHIEF MEDICAL OFFICER

    • Officer
    		 214,700 2023-01-23 3

    TANG CAROLYN C. GENERAL COUNSEL

    • Officer
    		 235,739 2023-01-23 4

    PERLMAN ANDREW J

    • Director
    		 27,925 2022-06-14 1

    FALBERG KATHRYN E

    • Director
    		 209,510 2022-06-14 1

    KANEKO YASUNORI

    • Director
    		 920,555 2022-06-14 1

    MACHADO PATRICK

    • Director
    		 26,900 2022-06-14 1

    LACEY DAVID L.

    • Director
    		 59,252 2022-06-14 1

    LAMBERT NICOLE

    • Director
    		 20,900 2022-06-14 1

    RIBAS ANTONI

    • Director
    		 40,503 2022-06-14 1

    HIGGINS LINDA SLANEC

    • Director
    		 0 2021-08-10 0

    GROSSMAN WILLIAM CHIEF MEDICAL OFFICER

    • Officer
    		 20,723 2021-06-16 0

    GILEAD SCIENCES INC

    • 10% Owner
    		 13,913,029 2021-01-31 0

    QUIGLEY MICHAEL

    • Director
    		 0 2021-01-06 0

    PARSEY MERDAD

    • Director
    		 0 2020-07-13 0

    BARKER JASON SEE REMARKS

    • Officer
    		 10,000 2020-06-04 0

    BEIER DAVID W

    • Director
    		 0 2019-06-06 0

    HEGE KRISTEN

    • Director
    		 0 2019-06-06 0

    HEMRAJANI REKHA SEE REMARKS

    • Officer
    		 0 2019-03-25 0

    CHAN STEVEN SEE REMARKS

    • Officer
    		 0 2019-01-16 0

    COLUMN GROUP II, LP

    COLUMN GROUP II GP, LP

    PONOI MANAGEMENT, LLC

    PONOI CAPITAL, LP

    GOEDDEL DAVID V

    SVENNILSON PETER

    KUTZKEY TIM

    • 10% Owner
    		 No longer subject to file 2018-03-19 0

    GV 2016 GP, L.L.C.

    GV 2016 GP, L.P.

    GV 2016, L.P.

    ALPHABET INC.

    • 10% Owner
    		 3,125,312 2018-03-19 0

    GV 2017 GP, L.L.C.

    GV 2017 GP, L.P.

    GV 2017, L.P.

    ALPHABET INC.

    • 10% Owner
    		 1,924,474 2018-03-19 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) II L.P.

    • 10% Owner
    		 No longer subject to file 2018-03-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ROSEN TERRY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-25 17:49:05 -0500 2023-01-23 A 429,000 a 429,000 direct

    NUYTEN DIMITRY SA - Officer CHIEF MEDICAL OFFICER

    		2023-01-25 17:55:09 -0500 2023-01-23 A 138,200 a 138,200 direct

    NUYTEN DIMITRY SA - Officer CHIEF MEDICAL OFFICER

    		2023-01-25 17:55:09 -0500 2023-01-23 A 34,000 a 76,500 direct 0.1732 0.1732 2 0.0 1

    GOELTZ II ROBERT C. - Officer CHIEF FINANCIAL OFFICER

    		2023-01-25 17:53:58 -0500 2023-01-23 A 138,200 a 138,200 direct

    GOELTZ II ROBERT C. - Officer CHIEF FINANCIAL OFFICER

    		2023-01-25 17:53:58 -0500 2023-01-23 A 34,000 a 63,441 direct 0.1732 0.1732 2 0.0 1

    TANG CAROLYN C. - Officer GENERAL COUNSEL

    		2023-01-25 17:52:48 -0500 2023-01-23 A 138,200 a 138,200 direct

    TANG CAROLYN C. - Officer GENERAL COUNSEL

    		2023-01-25 17:52:48 -0500 2023-01-23 A 34,000 a 97,539 direct 0.1732 0.1732 2 0.0 1

    JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER

    		2023-01-25 17:51:41 -0500 2023-01-23 A 185,900 a 185,900 direct

    JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER

    		2023-01-25 17:51:41 -0500 2023-01-23 A 45,800 a 416,846 direct 0.1732 0.1732 2 0.0 1

    JAEN JUAN C. - Director - Officer PRESIDENT

    		2023-01-25 17:50:28 -0500 2023-01-23 A 185,900 a 185,900 direct

    JAEN JUAN C. - Director - Officer PRESIDENT

    		2023-01-25 17:50:28 -0500 2023-01-23 A 45,800 a 324,682 direct 0.1732 0.1732 2 0.0 1

    ROSEN TERRY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-25 17:49:05 -0500 2023-01-23 A 105,700 a 469,123 direct 0.1732 0.1732 2 0.0 1

    ROSEN TERRY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2022-12-16 21:39:46 -0500 2022-12-16 S 10,983 $30.66 d 244,233 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    GOELTZ II ROBERT C. - Officer CHIEF FINANCIAL OFFICER

    		2022-12-16 21:44:26 -0500 2022-12-16 S 387 $31.23 d 11,566 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    GOELTZ II ROBERT C. - Officer CHIEF FINANCIAL OFFICER

    		2022-12-16 21:44:26 -0500 2022-12-16 S 2,066 $30.66 d 11,953 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    TANG CAROLYN C. - Officer GENERAL COUNSEL

    		2022-12-16 21:42:53 -0500 2022-12-16 S 398 $31.23 d 28,584 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    TANG CAROLYN C. - Officer GENERAL COUNSEL

    		2022-12-16 21:42:53 -0500 2022-12-16 S 2,125 $30.66 d 28,982 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER

    		2022-12-16 21:41:51 -0500 2022-12-16 S 2,603 $31.23 d 147,609 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER

    		2022-12-16 21:41:51 -0500 2022-12-16 S 13,879 $30.66 d 150,212 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    JAEN JUAN C. - Director - Officer PRESIDENT

    		2022-12-16 21:40:45 -0500 2022-12-16 S 701 $31.23 d 218,258 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    JAEN JUAN C. - Director - Officer PRESIDENT

    		2022-12-16 21:40:45 -0500 2022-12-16 S 3,735 $30.66 d 218,959 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    ROSEN TERRY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2022-12-16 21:39:46 -0500 2022-12-16 S 2,060 $31.23 d 242,173 direct -32.5139 -33.6283 0.0 1 -33.6283 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 22:15:03 UTC 4.0599 0.2601 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 21:45:04 UTC 4.0599 0.2601 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 21:15:04 UTC 4.0599 0.2601 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 20:45:03 UTC 4.0558 0.2642 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 20:15:04 UTC 4.0558 0.2642 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 19:45:03 UTC 4.0558 0.2642 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 19:15:03 UTC 4.0558 0.2642 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 18:45:04 UTC 4.0577 0.2623 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 18:15:03 UTC 4.0577 0.2623 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 17:45:03 UTC 4.0577 0.2623 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 17:15:04 UTC 4.0577 0.2623 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 16:45:03 UTC 4.0588 0.2612 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 16:15:03 UTC 4.0588 0.2612 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 15:45:03 UTC 4.0588 0.2612 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 15:15:04 UTC 4.0588 0.2612 1200000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 14:45:04 UTC 4.0588 0.2612 1200000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 14:15:03 UTC 4.0588 0.2612 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 13:45:03 UTC 4.0678 0.2522 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 13:15:03 UTC 4.0678 0.2522 1300000
    ARCUS BIOSCIENCES INC RCUS 2023-01-27 12:45:03 UTC 4.0678 0.2522 1300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund RCUS -1300.0 shares, $-3393.0 2022-09-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund RCUS -2817.0 shares, $-73692.72 2022-09-30 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund RCUS -874.0 shares, $-22269.52 2022-10-31 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund RCUS -333.0 shares, $-8484.84 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments